EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSBMUG00000000879
Gene Symbol: MAP3K9
3 Cross references
195 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSBMUG00000022286
Gene Symbol: MAOA
3 Cross references
147 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSBMUG00000022334
Gene Symbol: MAOB
3 Cross references
333 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSBMUG00000014951
Gene Symbol: MGLL
3 Cross references
209 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSBMUG00000001633
Gene Symbol: MLNR
3 Cross references
163 Possible Orthologues:

Myeloperoxidase

Ensembl ID : ENSBMUG00000020570
Gene Symbol: MPO
3 Cross references
182 Possible Orthologues:

Natriuretic Peptide Receptor 1

Ensembl ID : ENSBMUG00000026798
Gene Symbol: NPR1
3 Cross references
186 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSBMUG00000024207
Gene Symbol: NPR2
3 Cross references
260 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSBMUG00000010356
Gene Symbol: NPR3
3 Cross references
210 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSBMUG00000023935
Gene Symbol: NPY2R
3 Cross references
248 Possible Orthologues:

Neuropeptide Y Receptor Y4

Ensembl ID : ENSBMUG00000026777
Gene Symbol: NPY4R
2 Cross references
116 Possible Orthologues:

Neuropeptide Y Receptor Y5

Ensembl ID : ENSBMUG00000023182
Gene Symbol: NPY5R
3 Cross references
137 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).